Department of Systems Pharmacology and Translational Therapeutics (W.-L.S., E.R., X.L., T.G., G.A.F.), Institute for Translational Medicine and Therapeutics (W.-L.S., E.R., X.L., T.G., G.R.G., G.A.F.), and Perelman School of Medicine and Department of Genetics (G.R.G.), University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Systems Pharmacology and Translational Therapeutics (W.-L.S., E.R., X.L., T.G., G.A.F.), Institute for Translational Medicine and Therapeutics (W.-L.S., E.R., X.L., T.G., G.R.G., G.A.F.), and Perelman School of Medicine and Department of Genetics (G.R.G.), University of Pennsylvania, Philadelphia, Pennsylvania
J Pharmacol Exp Ther. 2018 Dec;367(3):425-432. doi: 10.1124/jpet.118.250936. Epub 2018 Oct 10.
Prostaglandin (PG) D is formed by two distinct PGD synthases (PGDS): lipocalin-type PGDS (L-PGDS), which acts as a PGD-producing enzyme and as extracellular lipophilic transporter, and hematopoietic PGDS (H-PGDS), a glutathione-S-transferase. PGD plays an important role in the maintenance of vascular function; however, the relative contribution of L-PGDS- and H-PGDS-dependent formation of PGD in this setting is unknown. To gain insight into the function played by these distinct PGDS, we assessed systemic blood pressure (BP) and thrombogenesis in L-Pgds and H-Pgds knockout (KO) mice. Deletion of L-Pgds depresses urinary PGD metabolite (PGDM) by ∼35%, whereas deletion of H-Pgds does so by ∼90%. Deletion of L-Pgds, but not H-Pgds, elevates BP and accelerates the thrombogenic occlusive response to a photochemical injury to the carotid artery. HQL-79, a H-PGDS inhibitor, further depresses PGDM in L-Pgds KO mice, but has no effect on BP or on the thrombogenic response. Gene expression profiling reveals that pathways relevant to vascular function are dysregulated in the aorta of L-Pgds KOs. These results indicate that the functional impact of L-Pgds deletion on vascular homeostasis may result from an autocrine effect of L-PGDS-dependent PGD on the vasculature and/or the L-PGDS function as lipophilic carrier protein.
前列腺素 (PG) D 由两种不同的 PGD 合酶 (PGDS) 形成:脂联素型 PGDS (L-PGDS),它作为 PGD 产生酶和细胞外亲脂性转运蛋白发挥作用,以及造血 PGDS (H-PGDS),一种谷胱甘肽-S-转移酶。PGD 在维持血管功能方面发挥着重要作用;然而,在这种情况下,L-PGDS 和 H-PGDS 依赖性 PGD 形成的相对贡献尚不清楚。为了深入了解这些不同的 PGDS 所发挥的功能,我们评估了 L-Pgds 和 H-Pgds 敲除 (KO) 小鼠的系统血压 (BP) 和血栓形成。L-Pgds 的缺失使尿 PGD 代谢物 (PGDM) 降低约 35%,而 H-Pgds 的缺失则降低约 90%。L-Pgds 的缺失会升高血压并加速对颈动脉光化学损伤的血栓形成闭塞反应,而 H-Pgds 的缺失则不会。HQL-79 是一种 H-PGDS 抑制剂,可进一步降低 L-Pgds KO 小鼠中的 PGDM,但对 BP 或血栓形成反应没有影响。基因表达谱分析显示,L-Pgds KO 主动脉中的血管功能相关途径失调。这些结果表明,L-Pgds 缺失对血管内稳态的功能影响可能是由于 L-PGDS 依赖性 PGD 对血管的自分泌作用以及 L-PGDS 作为亲脂性载体蛋白的功能所致。